Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/109389
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Coimbra, Susana | - |
dc.contributor.author | Figueiredo, Américo | - |
dc.contributor.author | Santos-Silva, Alice | - |
dc.date.accessioned | 2023-10-12T08:58:22Z | - |
dc.date.available | 2023-10-12T08:58:22Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1555-1741 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/109389 | - |
dc.description.abstract | Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis. | pt |
dc.language.iso | eng | pt |
dc.publisher | Dove Medical Press Ltd | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | pt |
dc.subject | interleukin-17 | pt |
dc.subject | interleukin-17 receptor | pt |
dc.subject | monoclonal antibody | pt |
dc.subject | T helper 17 pathway | pt |
dc.title | Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis | pt |
dc.type | article | - |
degois.publication.firstPage | 89 | pt |
degois.publication.lastPage | 97 | pt |
degois.publication.title | Core Evidence | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.2147/CE.S33940 | pt |
degois.publication.volume | 9 | pt |
dc.date.embargo | 2014-01-01 | * |
uc.date.periodoEmbargo | 0 | pt |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | Com Texto completo | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0002-9105-9619 | - |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Brodalumab-An-evidencebased-review-of-its-potential-in-the-treatment-of-moderatetosevere-psoriasisCore-Evidence.pdf | 465.07 kB | Adobe PDF | View/Open |
Page view(s)
38
checked on May 8, 2024
Download(s)
6
checked on May 8, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License